Nicole Lou

Senior Staff Writer at MedPage Today

new york, new york, united states

Publications:

Is this you?

Claim your profile to connect with sources, showcase your work, and earn extra income just by writing great stories.

About

Nicole Lou is a medical journalist with experience writing for both consumer and professional audiences. At MedPage Today, she reports on developments in cardiology, with other work appearing in NOVA Next, Popular Science, The Atlantic, Audubon, TCTMD, and VICE Motherboard. She studied Spanish and biology at Williams College and trained under NYU’s Science, Health, and Environmental Reporting Program.

Featured Articles

Etripamil Gets FDA Approval for At-Home Tachycardia Conversion | MedPage Today

The FDA approved etripamil (Cardamyst) nasal spray for at-home treatment of paroxysmal supraventricular tachycardia (PSVT), maker Milestone Pharmaceuticals announced . The rapid-acting L-type calcium channel blocker is indicated for converting acute sympt... See more

medpagetoday.com•Nicole Lou•Dec 15, 2025

FDA Panel on Interatrial Shunt for Heart Failure: It's a Hard No | MedPage Today

An FDA advisory panel gave a unanimous verdict for an interatrial shunt in heart failure: no way. All 15 members of the Circulatory System Devices Panel of the Medical Devices Advisory Committee on Wednesday voted that the benefits do not outweigh the ris... See more

medpagetoday.com•Nicole Lou•Dec 4, 2025

Online Tool Estimates Percentiles for Long-Term Cardiovascular Risk | MedPage Today

Key Takeaways Based on the PREVENT risk calculator, researchers developed age- and sex-specific percentiles for 30-year absolute risk estimates for cardiovascular disease. Framing risk relative to peers by age and sex is believed to improve communication ... See more

medpagetoday.com•Nicole Lou•Nov 17, 2025

Something Off About Recent Heart Failure Stem Cell Trial, Major Journal Admits | MedPage Today

The BMJ slapped an "expression of concern" on a much-publicized stem cell trial it published just 2 weeks ago. A boxed warning now lies at the top of the phase III study, PREVENT-TAHA8, which had reported that an intracoronary infusion of umbilical cord m... See more

medpagetoday.com•Nicole Lou•Nov 12, 2025

Amid Safety Investigation, ATTR Gene Therapy Buoyed by Good 3-Year Data

NEW ORLEANS -- Despite ongoing scrutiny about its safety, nexiguran ziclumeran (nex-z) still had promising effectiveness data to hold onto. In an update on nex-z's phase I study, the CRISPR-Cas9 gene therapy stayed the course out to 3 years in an initial ... See more

medpagetoday.com•Nicole Lou•Nov 12, 2025

Bylined Articles

HARO Queries

Portfolio

Is this you?

Claim your profile to connect with sources, showcase your work, and earn extra income just by writing great stories.

Claim your profile

Social Media

Pitching Guidelines

Keep it short (under 200 words)
Include credentials and links
Use subject lines with query title

Pitching Guidelines

Quick Stats

Followers

459

Articles44

Last Articlea month ago

Stats

Education

Master Of Arts, Journalism at New York UniversityGraduated: 2015

Bachelor Of Arts, Biology, Spanish at Williams CollegeGraduated: 2013

Art History, Literature at Universidad Autónoma De MadridGraduated: 2012

Education

Nicole Lou

Is this you?

About

Featured Articles

Etripamil Gets FDA Approval for At-Home Tachycardia Conversion | MedPage Today

FDA Panel on Interatrial Shunt for Heart Failure: It's a Hard No | MedPage Today

Online Tool Estimates Percentiles for Long-Term Cardiovascular Risk | MedPage Today

Something Off About Recent Heart Failure Stem Cell Trial, Major Journal Admits | MedPage Today

Amid Safety Investigation, ATTR Gene Therapy Buoyed by Good 3-Year Data

Is this you?

Social Media

Education

Connect with journalists.

Connect with journalists.

Featured Articles

Etripamil Gets FDA Approval for At-Home Tachycardia Conversion | MedPage Today

FDA Panel on Interatrial Shunt for Heart Failure: It's a Hard No | MedPage Today

Online Tool Estimates Percentiles for Long-Term Cardiovascular Risk | MedPage Today

Something Off About Recent Heart Failure Stem Cell Trial, Major Journal Admits | MedPage Today

Amid Safety Investigation, ATTR Gene Therapy Buoyed by Good 3-Year Data

Social Media

Education